Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

The use of Lenalidomide (LEN), to reverse tumor-mediated immune suppression and amplify multiple myeloma-specific immunity is currently being explored. Particularly, LEN effects on dendritic cells (DCs) are still unclear. In this study, we investigated the potential effect of LEN on DC differentiati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Costa, Federica, Vescovini, Rosanna, Bolzoni, Marina, Marchica, Valentina, Storti, Paola, Toscani, Denise, Accardi, Fabrizio, Notarfranchi, Laura, Dalla Palma, Benedetta, Manferdini, Cristina, Manni, Sabrina, Todaro, Giannalisa, Lisignoli, Gina, Piazza, Francesco, Aversa, Franco, Giuliani, Nicola
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581092/
https://ncbi.nlm.nih.gov/pubmed/28881793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18085
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados